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Background: Iodine has a significant effect on thyroid function. 
A dose of 200 ml of contrast agent contains 35 mg /ml equivalent of 
7000 Mg of free iodine and 45 times of the recommended daily dose. 
This high dose can cause a sudden loss of iodine adjustment, thyroid 
hormone synthesis, and impair the function of the thyroid gland. 
Methods: This study is a cross-sectional study (descriptive-analytical) 
conducted in census method on 70 patients including 40 men and 
30 women referring to Hajar medical education hospital for coronary 
angiography. Thyroid function tests were given before and after 
receiving the contrast agent angiography and the changes were finally 
analyzed. 
Results: In this study, after receiving iodinated contrast agent, 8 out 
of 70 cases studied significantly suffered subclinical hypothyroidism 
and no one suffered overt hypothyroidism or hypothyroidism. In 
terms of distribution based on age, there was no significant difference 
between different age groups in the intensity of hypothyroidism. In 
terms of gender distribution, from among 70 cases studied, 40 were 
men, of whom three suffered subclinical hypothyroidisms. Thirty of 
the subjects were women, of whom five persons suffered subclinical 
hypothyroidism. 
Conclusion: The results show that angiography contrast agent can 
have effects on the thyroid function of the people with euthyroid, so 
that out of the 70 patients studied, all of whom were euthyroid, eight 
patients suffered subclinical hypothyroidism. (p=0.018). Moreover, 
the age and sex of the participants had no effects on thyroid disorder 
after receiving angiography contrast agent (P=0.5).
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INTRODUCTION
The fundamental role of iodine in thyroid physiol-
ogy is well known. This scarce element form 65% of 
the weight of thyroxine hormone (T4) and 59% of 
weight of triiodothyronine (T3).  
The recommended daily intake of iodine is 
about 150-250 mcg. Excessive consumption of 
iodine either using iodine-containing food prod-
ucts or drug products containing iodine will lead 
to an increased incidence of autoimmune thyroid 
diseases. Iodized contrast agents are among the 
most frequently used drugs in modern medicine.1 
The use of these materials in cardiology and 
radiology may cause contrast-induced nephropathy, 
allergic reactions, CVA, and other complications.2 
These materials have a significant effect on thyroid 
function.3 The effects of prescribing iodine in patients 
with thyroid gland disorders are different compared 
to normal subjects and depend on thyroid gland 
diseases. For example, iodine therapy in patients 
with endemic goiter or nodular goiter where the 
tissue has autonomic function cause hyperthyroid. 
Thyrotoxicosis caused by iodine is more 
common in areas where there is iodine deficiency,4 
so that the prevalence of 1-30% of hyperthyroid-
ism after iodine intake has been reported in these 
areas.5,6 At the same time, thyrotoxicosis caused by 
iodine can happen in places where iodine is used 
sufficiently.7 Thyrotoxicosis caused by iodine even 
happens in apparently normal thyroid glands.8 A 
dose of 200 ml of contrast agent contains 35 mg /ml 
equivalent of 7000 Mg of free iodine and 45 times 
of the recommended daily dose.8 This high dose 
can cause a sudden loss of iodine adjustment and 
thyroid hormone synthesis causing hyperthyroid-
ism, a phenomenon called Jod-Basedow effect.9 
Iodine-induced hyperthyroidism has been reported 
in patients with thyroid disease, but it mainly occurs 
in patients with thyroid nodules.10 More hyperthy-
roidism is seen following iodine therapy (10-20%) 
in patients with nodular goiter living in iodine 
deficient areas.11 Such patients may have subclinical 
hyperthyroidism before iodine therapy.6 Iodine-
induced hyperthyroidism is rare in patients without 
thyroid disease.12
In contrast, iodine therapy in patients with auto-
immune thyroiditis can lead to hypothyroidism or 
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aggravating it. Patients at risk of iodine-induced 
hypothyroidism include: 1) People with chronic 
autoimmune thyroiditis, 2) patients with Graves’ 
disease who have previously been treated with 
radioactive iodine or by thyroidectomy, and 3) 
patients with subacute thyroiditis, postpartum 
thyroiditis, and painless thyroiditis.13-15,16 Such 
patients are unusually sensitive to the inhibitory 
effects of iodine in organification stage of iodine 
(Wolff–Chaikoff effect), so that iodine causes the 
constant activity of iodine/sodium transferor.13 
This continuous activity of the transferor leads to 
long-term inhibition of the synthesis of thyroid 
hormones resulting in an increase in TSH concen-
trations of serum. Hypothyroidism happens in 
the patients due to impaired escape from Wolff–
Chaikoff effect.
Clinical hypothyroidism caused by iodine 
is similar to other hypothyroidism causes. 
Hypothyroidism caused by iodine in healthy 
people normally stops spontaneously within one 
or two weeks after discontinuation of iodine 
use.17-19 Most patients do not need thyroid 
hormone replacement. Recovery time may be 
longer in patients who have been exposed to mate-
rials that contain iodine not rapidly eliminated 
from the body (8 weeks or more). In such patients 
or in cases where the iodine source cannot be 
eliminated (such as taking amiodarone) thyroid 
function can easily be normalized with replace-
ment of T4, while the patient is still exposed to 
iodine. Because of the underlying thyroid disease, 
patients who risk of temporary iodine-induced 
hypothyroidism are at risk of permanent hypo-
thyroidism in the future.
Subclinical hypothyroidism is another side 
effect of subclinical hypothyroidism iodine, 
where the concentration of serum TSH is higher 
than normal but T4 serum T3 concentrations are 
normal. Although there is comprehensive agree-
ment on treatment of patients with subclinical 
hypothyroidism with serum TSH level higher 
than 10 mIU/L,20,23 about the treatment of 
patients with subclinical hypothyroidism with 
serum TSH levels between 5-10 mIU/L, there is 
still no general agreement.24,25 In Iran, two studies 
have been conducted in this area. The first study 
was conducted in Shiraz on 48 patients, who 
underwent coronary angiography with urografin 
contrast agent. In that study, it was noted that 
“coronary angiography with the contrast agent 
had no significant effect on thyroid function, 
but in rare cases, in the first few weeks after 
coronary angiography, it can cause hyperthy-
roidism.26 The aim of this study was to find an 
appropriate solution in the follow-up of patients 
undergoing coronary angiography to start timely 
treatment and to prevent complications of thyroid 
dysfunction in patients with heart diseases, and to 
suggesting the referral of the patients to special-
ists in internal medicine, cardiology, and endocri-
nology after coronary angiography.
METHODS
This study is cross-sectional (descriptive - analytic) 
conducted to prove hypotheses put forward on 
patients admitted to cardiac ward of Hajar hospi-
tal in Shahrkord. People underwent angiography 
of coronary artery in angiography unit of Hajar 
Hospital. All subjects were 70 cases, of whom 40 
were male and 30 were female.
Inclusion Criteria 
Everyone who underwent coronary angiography 
with iodine contrast agent were included in the 
study, and those who did not have conditions for 
the study were excluded from the study.
Exclusion Criteria 
1) Any person who had a personal history of thyroid 
disease was excluded from the study. 2) People who 
have abnormal thyroid function tests before angiog-
raphy were excluded from study. 3) All people who 
had nodule thyroid or goiter in the thyroid ultra-
sound performed before were excluded. 4) People 
using drugs containing iodine such as amiodarone 
were excluded from the study. 5) People who used 
drugs affecting thyroid function were excluded as 
well.
Sample Size and Sampling 
In this study, 67 samples are required and about 
70 people participated in the study. The sampling 
was done in census mode where the patients were 
randomly selected from among those referring to 
Heart Center of Hajar hospital, Shahrekord who 
needed for coronary angiography. Variables include 
age, sex, TSH, FreeT3, and FreeT4.
Data Collection and Tools
In a separate checklist prepared for each patient, 
thyroid tests result, age, sex, and thyroid sonogra-
phy results were recorded before angiography, and 
then the patients underwent coronary angiography 
after receiving the contrast agent. One month after 
discharging from the hospital, the patients were 
contacted to refer to the hospital and do thyroid 
tests and the results were recorded. In this study, 
all patients, from October 23, 2013 to January 21, 
2014, who had the entry criteria, entered the study. 
From Everyone who met inclusion criteria were 
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enrolled. Information form was designed in the 
form of a questionnaire that did not need validity 
and reliability.
The sample size according to the statistical coun-
selor was determined 70. Due to exclusion crite-
ria, of the 70 patients, 40 patients were male and 
30 were female. First, the complete history of the 
patient’s underlying disease, including thyroid and 
using iodine-containing drugs were taken and then 
physical examination was done for thyroid nodules 
and goiters. If the patient had had the exclusion 
criteria, he would have been removed from the 
study; otherwise, they entered the study and 
thyroid function tests and thyroid sonography were 
performed. Thyroid tests were TSH, FT4, and FT3. 
A physician radiologist at the ultrasound center of 
Hajar hospital performed thyroid ultrasound. Then 
coronary angiography was being performed and 
then 4 weeks later the patients were given thyroid 
function tests, including FT4, FT3 and TSH. The 
contrast agent used, on average, was 50ml where 
average iodine in it was 320 mg/ml. Data analysis 
method was through frequency distribution and 
percentage for qualitative data, for quantitative 
data, average standard deviation, and pairwise 
t-test was used for statistical analysis.
RESULTS
In studies that had been done in the past, in most 
cases, the patients had suffered hyperthyroidism 
after receiving contrast. In the study by Martin et 
al., hyperthyroidism has been shown after the use of 
contrast agents.27 In another study, only two patients 
out of 788 patients of hyperthyroidism iodine defi-
ciency suffered hyperthyroidism 12  weeks after 
angiography, and so in this study, it was found that 
in adult patients without morphological changes of 
the thyroid gland and thyroid function, thyroid test 
is a single dose and high contrast agent are safe.28 
In one study where patients underwent IVP, T4 
increased, TSH decreased, but T3 did not change. 
Two patients suffered hyperthyroid and 1 suffered 
AF.29 In Iran, two studies have been conducted in 
this area. The first study was conducted in Shiraz on 
48 patients, who underwent coronary angiography 
with urografin contrast agent. In that study, it was 
noted that coronary angiography with the contrast 
agent had no significant effect on thyroid function, 
but in rare cases, in the first few weeks after coro-
nary angiography, it can cause hyperthyroidism.26 
In another study, conducted in Kermanshah, it 
was noted that coronary angiography with iodized 
contrast agent has a significant effect on thyroid 
function test, and after the first few weeks after 
coronary angiography, it may cause hyperthyroid. 
This side effect in the elderly and people who have 
coronary artery disease can be dangerous.30
In 2013, a study was conducted on 101 patients 
with euthyroid in Turkey who underwent coro-
nary angiography. The results of this study showed 
that TSH levels of patients significantly decreased 
during the fourth and eighth weeks after treatment. 
In this study, all the patients, before angiography, 
underwent thyroid and thyroid sonography, so 
that all normal patients are completely enter the 
study. According to the study, the risk of devel-
oping subclinical hypothyroidism after receiving 
the contrast agent containing iodine has been 
proposed.31
Based on Paired Samples Correlations, the 
comparison between the thyroid hormones before 
and after angiography in men is as follows (Fig. 1).
- There is a significant correlation between T3 
before and after coronary angiography (p = 0.014).
- There is no significant correlation between T4 
before and after coronary angiography.
- There is a significant correlation between TSH 
value before and after coronary angiography with 
correlation coefficient of 0.67.
Based on these data and based on Paired Samples 
Correlations, there is a significant relationship in 
comparison between thyroid hormones before and 
after angiography, according to Table 2 separately 
for women groups, T3, T4 and TSH before and after 
coronary angiography.
In this study, subjects were divided into three 
age groups: the age group 20-39, 40-59, and 60 
years of age years (Fig. 3). Based on Paired Samples 
Correlations test, there is a correlation between 
thyroid hormones levels before and after angiog-
raphy according to Table (3) separately in the age 
group 20-39 years in T3 and TSH, before and after 
coronary angiography, which is meaningful. 2. 
There is a correlation between T4 before and after 
angiography with correlation coefficient 0.27 that is 
not significant (p=0.119).
Based on Paired Samples Correlations test, 
there is a correlation between thyroid hormones 
levels before and after angiography according to 
Table  4 separately in the age group 20-39 in T3, 
with correlation coefficient 0.75, which is not 
Table 1  Thyroid hormone levels before and after coronary 
angiography in men
Before angiography After angiography
Correlation 
coefficient P
T3 0.4 ± 1.29 0.4 ± 1.4 0.38 0.014
T4 1.12± 7.22 1.8 ± 7.86 0.26 0.105
TSH 2.01± 2.63 2.16± 2.25 0.67 0.001
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meaningful (p=0.119).  2. There is a significant 
correlation between T4, TSH before and after angi-
ography in the age group 40-59.
Based on Paired Samples Correlations test, there 
is a correlation between thyroid hormones levels 
before and after angiography according to Table 5 
separately in the age group 60 in T3, with correla-
tion coefficient 0.16, which is not meaningful. 
There is a significant correlation between T4, TSH 
before and after angiography.
The effect of coronary angiography iodized 
contrast agent on thyroid function in people 
without thyroid gland disorders, regardless of age 
and gender, is obtained as follows. According to 
Figure 1, all people without thyroid gland disorder 
that met the inclusion criteria were 70, of whom 8 
patients suffered subclinical hypothyroidism after 
receiving iodized contrast agent and no patient 
developed hypothyroidism or overt hyperthyroid-
ism (P=0.018).
In terms of gender distribution from among 
the 70 cases studied, 40 were male, of whom after 
receiving the iodinated contrast agent, no one 
suffered overt hypothyroidism or hyperthyroidism, 
but three patients suffered subclinical hypothyroid-
ism. Thirty persons of the subjects were women, of 
whom after receiving iodinated contrast agent, no 
one suffered overt hypothyroidism or hypothyroid-
ism, but five persons suffered subclinical hypothy-
roidism (Figure 2). Based on Independent Sample 
Test, in terms of suffering hypothyroid, there is 
no difference between male and female gender in 
hypothyroid (P=0.167).
In terms of distribution of age, 70 studied 
patients were divided into three age groups. In 
the age group 20-39, the number of people was 
three, none of whom suffered thyroid disorder 
after receiving iodinated contrast agent. In the age 
group 40-59, the number was 34 that after receiv-
ing iodinated contrast agent no one suffered overt 
hyperthyroidism and hypothyroidism, but four 
people suffered subclinical hypothyroidism.
The number of people in age group 60 and over 
was 33 people that after receiving iodinated contrast 
agent, no patient suffered overt hyperthyroidism 
and hypothyroidism, but four people suffered 
subclinical hypothyroidism (Figure 3). Based on 
analysis of variance (One Way Anova), in terms 
of suffering hypothyroid, there was no significant 
difference between three age groups (P=0.5).
CONCLUSION
In this study that was conducted in Shahrekord 
(Chaharmahaland Bakhtiari Province) on 70 
people, no cases had hyperthyroidism up to four 








T3 0.38 ±1.36 0.39 ±1.38 0.57 0.001
T4 1.19± 7.78 1.27± 7.21 0.37 0.042
TSH 1.46± 2.3 2.02± 2.856 0.72 0.001
Table 3  Thyroid hormone levels before and after coronary 







T3 0.37 ± 1.26 0.39 ± 1.34 0.75 0.001
T4 1.52± 7.9 1.23± 7.21 0.27 0.119
TSH 2.51± 2.28 2.03± 2.62 0.79 0.001
Table 4  Thyroid hormone levels before and after coronary 







T3 0.37 ± 1.25 0.4 ± 1.34 0.75 0.119
T4 1.52± 7.9 1.23± 7.39 0.27 0.001
TSH 1.51± 2.28 2.03± 2.62 0.79 0.001
Table 5  Thyroid hormone levels before and after coronary 







T3 0.4 ± 1.38 0.4 ± 1.45 0.26 0.387
T4 1.17± 7.58 1.7 ± 8.09 0.36 0.038
TSH 2.08± 2.76 2.04± 2.81 0.6 0.001
Figure 1  The effect of iodized contrast agent of coronary angiography on the 
thyroid function in people without thyroid gland disorder
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weeks after coronary angiography in euthyroid 
individuals without thyroid disease. In eight cases, 
there was TSH increase without changes at T3 and 
T4; in fact, these patients suffered subclinical hypo-
thyroidism, and no cases of overt hypothyroidism 
were observed. Overall, of 70 patients studied all of 
whom were euthyroid without thyroid construction 
diseases, and only eight patients suffered subclini-
cal hypothyroidism. In terms of impact of gender 
on the effect of iodized contrast agent of coronary 
angiography on thyroid function, from among 40 
men, after subclinical hypothyroidism angiography, 
three patients suffered subclinical hypothyroidism. 
From among 30 women, after subclinical hypo-
thyroidism angiography, five patients suffered 
subclinical hypothyroidism. From among these 
people, neither in women nor in men, there were 
cases of overt hypothyroidism or hyperthyroidism. 
According to independent sample test, gender has 
no role in suffering hypothyroid between women 
and men (p=0.167). In terms of changes in thyroid 
function tests separately for men and women in age 
groups, it can be said that between men, there was no 
significant relationship between T4 changes before 
and after angiography, (P=0.105), but changes in 
other tests after coronary angiography compared to 
before had significant and growing changes. 
Among women, all the tests showed significant 
increase compared to before (P<0.05), but given our 
analysis of the thyroid tests is in form of combined 
analytical tests T3, T4 and TSH are generally not 
significant. People in the age group 20-39are three 
people that after receiving the contrast agent, none 
suffered impairment in thyroid function. In other 
words, no patient suffered hypothyroidism or thyro-
toxicosis after 4 weeks. People in the age group 
40-59who were 34 patients, after receiving contrast 
agent, only four people suffered from subclinical 
hypothyroidism (SCH). In people in the age group 
60 or more who were 33 subjects, after receiving 
contrast agent, four people developed subclinical 
hypothyroidism (SCH). In none of the age groups, 
cases of overt hypothyroidism (OH) and hyperthy-
roidism were observed. Based on analysis of variance 
(One Way Anova), in comparison between three age 
groups, there was no significant difference in the 
presence of hypothyroidism (p=0.5). Therefore, it can 
be concluded that age had no effect on hypothyroid 
of patients. The impact of age on the effect of contrast 
agent on thyroid function tests showed no changes 
only in the age group 20-39between T4 before and 
after the test (0.119), and other related variables had 
changes in form of increasing. In the group 40-59, 
except for T3 the rest of the data were significantly 
correlated (P<0.018). In the analysis of the results, 
in every thyroid test, each thyroid test changes after 
angiography compared to before, it can be seen that 
although some of these changes are significant, they 
have no effect on the overall results of the study, and 
have no clinical value.
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